71.05
-0.42 (-0.59%)
| Previous Close | 71.47 |
| Open | 71.47 |
| Volume | 127,581 |
| Avg. Volume (3M) | 1,794,205 |
| Market Cap | 2,391,545,088 |
| Price / Earnings (TTM) | 66.40 |
| Price / Earnings (Forward) | 52.36 |
| Price / Sales | 8.27 |
| Price / Book | 12.44 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 - 2 May 2025 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.42 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 155.00 (Evercore ISI Group, 118.17%) | Buy |
| Median | 142.00 (99.87%) | |
| Low | 115.00 (Stifel, 61.87%) | Hold |
| Average | 136.00 (91.43%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 113.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 14 Oct 2025 | 142.00 (99.87%) | Buy | 110.90 |
| 15 Jul 2025 | 142.00 (99.87%) | Buy | 115.68 | |
| Jefferies | 13 Oct 2025 | 145.00 (104.10%) | Buy | 110.90 |
| Evercore ISI Group | 16 Sep 2025 | 155.00 (118.17%) | Buy | 119.15 |
| Stifel | 04 Sep 2025 | 115.00 (61.87%) | Hold | 104.05 |
| Morgan Stanley | 01 Aug 2025 | 123.00 (73.13%) | Hold | 120.55 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 Sep 2025 | Announcement | TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy |
| 25 Aug 2025 | Announcement | TransMedics to Present at Upcoming September Investor Conferences |
| 04 Aug 2025 | Announcement | TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial |
| 01 Aug 2025 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 30 Jul 2025 | Announcement | TransMedics Reports Second Quarter 2025 Financial Results |
| 29 Jul 2025 | Announcement | TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference |
| 16 Jul 2025 | Announcement | TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |